Abbreviations {#sec0005}
=============

NOCBCa

:   Non-organ confined bladder cancer

RC-LND

:   radical cystectomy and pelvic lymph node dissection

PSC

:   presurgical chemotherapy

CSS

:   cancer specific survival

pCR

:   pathologic complete response

BCa

:   bladder cancer

mBCa

:   metastatic bladder cancer

OS

:   overall survival

RFS

:   recurrence free survival

AJCC

:   American Joint Committee on Cancer classification

MIBC

:   muscle invasive bladder cancer

TURBT

:   transurethral resection of bladder tumor

EUA

:   exam under anesthesia

LN

:   lymph node

ERAS

:   enhanced recovery after surgery

NMIBC

:   non-muscle invasive bladder cancer

LND

:   lymph node density

CR

:   complete response

UTUC

:   upper tract urothelial carcinoma

LT

:   local treatment

RARC

:   robotic-assisted radical cystectomy

INTRODUCTION {#sec0010}
============

Recently, local extirpative surgery has been increasingly integrated into the multimodal approach to metastatic disease arising from a wide range of solid tumors \[[@ref001]\]. In theory, local treatment can be beneficial in three ways: 1. Eradicate residual disease after favorable response to presurgical systemic therapy; 2. Minimize disease burden and improving the response to adjuvant systemic therapy; 3. Palliate symptoms related to locally advanced disease. Specifically for BCa, high incidence of relapse has been demonstrated at chemo-sensitive sites of disease, emphasizing the importance of consolidative surgical extirpation \[[@ref004]\]. Along these lines, RC-LND may lead to improved RFS and OS in patients with metastatic bladder cancer (mBCa).

Albeit the gold standard for organ-confined BCa \[[@ref005]\], RC-LND is associated with high perioperative morbidity. Mean length of hospital stay after RC-LND ranges between 9--11 days \[[@ref006]\], with high complication (58--77%) and readmission (27%) rates even at high-volume centers \[[@ref008]\]. Hence, RC-LND could only be utilized selectively, especially in the elderly and frail population afflicted by mBCa. Additionally, a complex array of clinical scenarios exist in NOCBCa, making the interpretation of existing data difficult. Finally, recent updates in the American Joint Committee on Cancer (AJCC) classification downgrading common iliac nodal disease from M1 to N3 status made many previous studies obsolete \[[@ref011]\]. In this review, we aim to systematically analyze the existing data on RC-LND performed in four different clinical scenarios of NOCBCa as illustrated by four index patients: 1. Locally advanced/unresectable disease (cT4bN0M0); 2. Occult pelvic nodal disease (pN+) (cTxN0M0 and pTxN1-3Mx); 3. Clinical node positive disease (cN+) (cTxN1-3M0); and 4. Distant metastatic disease (TxNxM1) ([Fig. 1](#blc-4-blc170130-g001){ref-type="fig"}).

![Flow diagram of patient categories and method of therapy.](blc-4-blc170130-g001){#blc-4-blc170130-g001}

CURRENT MANAGEMENT {#sec0015}
==================

Cisplatin-based combination chemotherapy has been the standard-of-care for NOCBCa since the late 1980's \[[@ref012]\]. Despite clear survival benefits, life expectancy after treatment remains poor. For instance, OS in mBCa patients after chemotherapy range between 12.5--14.8 months \[[@ref012]\]. Prognosis is especially poor after post-chemotherapy relapse, with median OS falling short of 8 months \[[@ref015]\]. Although recent advances in immunotherapy have offered hope to many mBCa patients failing cisplatin-based chemotherapy, objective response rates remain relatively low (between 15--21%) \[[@ref016]\]. Despite their modest response rates, as of this writing, five immune checkpoint blockade agents have been approved by the FDA, with two also showing efficacy as first-line agents in the cisplatin ineligible population \[[@ref016]\].

Due to the relative lack of evidence demonstrating benefit of local control, RC-LND has not been incorporated into treatment guidelines for NOCBCa in its current iteration \[[@ref005]\]. Consequently, local disease progression may lead to symptoms such as intractable hematuria and obstructive uropathy, severely compromising quality of life and requiring repeated invasive palliative procedures \[[@ref017]\].

THE IMPACT OF IMPERFECT CLINICAL STAGING {#sec0020}
========================================

The management of MIBC has been undercut by the lack of accurate staging tools \[[@ref019]\]. Clinical tumor staging consists of clinical and pathologic findings on TURBT and examination under anesthesia (EUA), while cross-sectional imaging is relied upon for the detection of perivesical, nodal and metastatic spread. Although CT urography has been the most widely used imaging modality, its accuracies for staging both the primary tumor as well as metastatic disease remain woefully inadequate. In evaluating the primary tumor, CT is unable to distinguish between Ta to T3a tumors \[[@ref020]\]. Moreover, as assessment of nodal metastases by CT is based solely on size. As a result, poor sensitivity (31%) results from its inability to detect small-sized nodal metastases \[[@ref021]\]. Despite offering enhanced soft tissue visualization, MRI only yielded incrementally improved accuracies of 63% compared to 56% by CT \[[@ref022]\]. In practice, the incidence of occult nodal metastases was found to be as high as 40% in patients with high clinical risk features \[[@ref023]\].

Ultimately, inaccurate clinical staging can lead to both unintended overtreatment in patients with occult metastatic and/or locally advanced disease and undertreatment in patients with pseudometastatic disease. To recapitulate the clinical conundrum resulting from the imperfect clinical staging tools, two index patients with lymph node (LN) metastases were created. Index patient 2 represents clinical understaging. To understand the role of surgical extirpation in this setting, data from historical surgical series without the use of PSC were analyzed. On the other hand, index patient 3 represents the common clinical scenario with cN+ disease. In interpreting the results of cN+ series, the readers must be reminded that many of the included studies did not require histologic proof of nodal metastases prior to treatment. Thus, improved outcomes may reflect inclusion of patients with false positive clinical nodal metastases.

INDEX PATIENT 1: CT4B DISEASE IN THE ABSENCE OF DISTANT DISEASE {#sec0025}
===============================================================

Prior to analyzing the existing literature on the efficacy of RC-LND for T4b BCa, the important distinction between cT4b and pT4b must be emphasized. cT4b BCa is defined by fixation on EUA after TURBT and/or evidence of direct invasion of an adjacent organ (other than prostate, vagina, or uterus) on cross sectional imaging \[[@ref019]\]. On the other hand, pT4b BCa represents direct invasion of the abdominal/pelvic wall on histologic examination of the RC-LND specimen. While many studies have documented the futility of extirpative surgery in treating pT4b BCa \[[@ref024]\], few have assessed the efficacy of a multimodal approach incorporating RC-LND to cT4b BCa.

That cT4b BCa may be more effectively treated by cisplatin-based chemotherapy followed by surgery than other forms of metastatic BCa was first suggested by Fossa et al. \[[@ref027]\]. In this study, observed response rate to chemotherapy in cT4b BCa patients was 57%, with 28% achieving CR. Moreover, 5-year OS was 25% in these patients, higher than those achieved in others with LN, lung or other sites of metastases. Even without the aid of robotic surgical technology and the modern day ERAS protocol, consolidative RC-LND was rendered to 28 of 245 patients with cT4b or pelvic nodal metastases. Subsequently, Herr et al. further strengthened the case for post-chemotherapy surgery by demonstrating 41% OS in patients achieving CR by way of multimodal treatment \[[@ref028]\]. However, due to the small cohorts, neither study identified favorable prognostic indicators in cT4b patients receiving combination chemotherapy/RC-LND.

To date, Black et al. performed the only study specifically examining the pathologic features and survival in cT4b patients undergoing RC-LND. In 23 patients, 30% were found to have pT4 BCa, while 26% were downstaged to NMIBC. Although only 3 patients were found to have a positive surgical margin, this did confer a poorer CSS (HR 5.3; 95% CI: 1.25--22.8, *p* = 0.024). In addition, pathologic nodal metastasis also predicted poorer CSS (HR 29.3; 95% CI: 3.1--275, *p* = 0.003). Remarkably, 5-year CSS in this group was 60% \[[@ref029]\]. Although limited by the small cohort size, results of this study suggested that RC-LND can be efficacious in a select group of patients with cT4b BCa.

INDEX PATIENT 2: OCCULT NODE POSITIVE DISEASE {#sec0030}
=============================================

Skinner was the first to demonstrate that long term survival was attainable in some BCa patients with nodal metastases following surgical resection \[[@ref030]\]. Thereafter, many small retrospective series demonstrated 5-year postoperative survival ranging from 29--39.4% \[[@ref031]\] ([Table 1](#blc-4-blc170130-t001){ref-type="table"}). In the two largest series to date, 10-year RFS was 34% per Stein et al. \[[@ref006]\] and CSS was 16.7% per Hautmann et al. \[[@ref036]\]. However, the survival benefit specifically derived from RC-LND is difficult to assess.

###### 

pN+ disease without presurgical chemotherapy

  Study (year)           Number of patients   \% of RC-LND patients          Follow up         Survival
  --------------------- -------------------- ----------------------- ------------------------- ------------------------------------
  Lerner (1993)                 132                    22%            5.5 yrs (2.6--18.8 yrs)  Median PFS 1.5 rys, 5 yr OS 29%
  Aprikian (1995)                25                   21.6%           2.2 yrs (0.6--8.7 yrs)   Median OS 2.3 yrs, 3 yr OS 33%
  Vieweg (1999)                 193                   25.3%                   7.7 yrs          Median OS ∼2 yrs, 5yr OS 31.2%
  Mills (2001)                   83                    18%                      --             Median OS 1.7 yrs, 5 yrs OS 29%
  Stein (2003)                  244                    23%             \>10 yrs (0--28 yrs)    5 yrs RFS 35%
  Frank (2003)                  154                    --             4.5 yrs (0.1--13.9 yrs)  Median CSS 4.5 yrs, 5 yr CSS 39.4%
  Madersbacher (2003)           124                    24%            3.8 yrs (0.1--14.7 yrs)  5yr OS 26%

Incident in 18--24% of all patients undergoing RC-LND without PSC \[[@ref006]\], pN+ BCa garnered much attention and many studies were performed to identify prognosticators for postsurgical survival. Early on, many recognized that even in patients with pN+ BCa, pathologic T staging continued to play an important role \[[@ref035]\]. In his analysis of 244 patients with pN+ BCa, Stein et al. found 10-year RFS to be 44% in patients with organ confined BCa compared to 30% in those with extravesical extension (*p* = 0.003) \[[@ref038]\].

Similarly, high LN disease burden was found to portend poor survival \[[@ref031]\]. Whereas early reports differentiated survival based on N staging \[[@ref031]\], others found cutoffs in the number of metastatic LNs to be prognostic for short survival \[[@ref006]\]. For example, Stein et al. found patients with more than 8 nodal metastases having a dismal 10-year RFS of 10%, compared to 40% in those with lighter metastatic burden \[[@ref038]\]. In another study consisting of 154 pN+ BCa patients, the optimal threshold for prognosticating CSS was found to be 5 \[[@ref032]\], corroborating many previous reports \[[@ref006]\]. In addition, the number of LNs retrieved during surgical resection was also found to be prognostic \[[@ref038]\]. In a secondary analysis of the data from SWOG 8710, Herr et al. pinpointed 10 LNs as the minimum requirement for conferring higher RFS and OS in pN0 and pN1 patients \[[@ref041]\]. Incorporating both the number of metastatic LNs and LNs retrieved, Stein et al. coined the term lymph node density (LND) and found a cutoff of 20% having prognostic value for RFS (43% 10-year RFS if LND \<20% vs. 17% 10-year RFS if LND \>20%, *p* \< 0.001). The prognostic value of LND was subsequently confirmed independently, albeit at a slightly different value of 25% \[[@ref042]\]. Other features of nodal metastases shown to be relevant to OS include extracapsular extension and nodal metastasis diameter \>0.5 cm \[[@ref034]\].

In addition to the nodal yield, template of node dissection had also been shown to impact survival. In an inter-institutional study comparing a limited nodal dissection template (encompassing the area on the pelvic sidewall between the genitofemoral nerve laterally, the obturator nerve medially, bifurcation of the common iliac vessels proximally and the circumflex iliac vessels distally) to an extended template (additionally encompassing tissue adjacent to the common iliac vessels caudad to the ureteral crossing and medial and lateral to the internal iliac vessels), 5-year RFS post extended LND was found to be superior in pN+ patients (35% vs. 7%) \[[@ref043]\]. However, a subsequent study failed to find survival benefit in patients undergoing superextended LND, which also included retroperitoneal nodes below the inferior mesenteric artery \[[@ref044]\].

The implication on survival due to nodal metastases found over the common iliac vessels had been a historical point of contention. The 6th edition of the AJCC staging system defined these nodes as metastatic disease (M1), suggesting significantly worse outcomes compared to patients with regional nodal disease within the true pelvis. However, a review by Steven and Poulsen revealed that 5-year OS was similar between patients with nodal metastases above and below the bifurcation of the common iliac vessels \[[@ref045]\]. Since, three additional studies confirmed the lack of prognostic difference between common iliac and pelvic nodal metastases \[[@ref046]\], justifying its N3 classification in the 7th AJCC staging system.

Taken together, surgeons performing RC-LND should aim to completely remove nodal tissue within the true pelvis and the common iliac templates up to the ureteral crossing. With thorough dissection, RC-LND consistently renders 29--39.4% of patients with pN+ BCa cancer free 5 years postoperatively. Patients with low nodal metastatic burden as well as organ confined primary disease seem to derive the most benefit from this procedure.

More controversially, adjuvant chemotherapy may also improve survival in pN+ BCa patients after RC-LND. As the majority of recurrences occurred at distant sites, failure of cancer control was attributed to systemic disease spread \[[@ref037]\]. In line with this, Madersbacher et al. found prolonged CSS in pN+ patients receiving adjuvant chemotherapy (21.5 mo vs. 13.1 mo) \[[@ref037]\]. This finding was corroborated in another study, in which adjuvant chemotherapy was found to reduce cancer specific mortality 2.1 fold (*p* = 0.005) \[[@ref032]\]. In contrast, several earlier studies failed to demonstrate survival benefit in patients receiving adjuvant chemotherapy \[[@ref033]\]. Different findings amongst these studies may be attributed to their smaller sample size or suboptimal chemotherapy regimen.

INDEX PATIENT 3: CLINICAL NODE POSITIVE DISEASE {#sec0035}
===============================================

After the emergence of level I evidence in support of using PSC prior to RC-LND \[[@ref049]\], a few studies investigated the role of combination therapy in treating the high risk MIBC patients with clinical nodal metastasis (cN+). A group from the Netherlands reported median CSS of 20 months and 5-year CSS in 29.2% \[[@ref051]\]. In comparison, median CSS and 5-year CSS in the patients rendered disease free on the pathologic specimen after PSC (pCR) were 127 months and 63.5%, respectively \[[@ref051]\]. On multivariate analysis, pCR was found to be a significant predictor of CSS. In a smaller cohort, Ho et al. confirmed the important prognostic role of pCR, demonstrating 5-year CSS in 83.3% \[[@ref053]\]. Notwithstanding its prognostic importance, pCR was found in just 14.5% of patients in a North American multi-institutional study consisting of 304 cN1-3 BCa patients treated with combination therapy \[[@ref054]\]. Surprisingly, 38% with CR at the primary tumor site (pT0) were found to have persistent metastatic LNs. Survival in patients with pCR were in line with previous findings. On multivariate analysis, surgical margin and nodal yield of at least 15 were found to be significant predictors of OS, underscoring the importance of complete surgical consolidation after PSC.

To further examine the value of consolidative RC-LND, two recent studies compared surgical resection and conservative management following chemotherapy for patients with cN+ BCa. Necchi et al. demonstrated improved PFS and OS in patients undergoing consolidative surgical lymphadenectomy after achieving CR with chemotherapy \[[@ref055]\]. However, these results were difficult to interpret as the cohort included both cN+ patients on primary diagnosis as well as recurrence after RC-LND. Furthermore, the relatively small sample size consisted of both cN+ BCa and UTUC patients, arguably two distinct disease entities.

More convincing evidence emerged from an analysis of 1,104 cN+ BCa patients within the National Cancer Data Base (NCDB) undergoing chemotherapy alone, cystectomy alone, PSC followed by RC-LND, and RC-LND followed by adjuvant chemotherapy \[[@ref056]\]. While 5-year OS following chemotherapy (14%; 95% CI: 11--17%) and cystectomy (19%; 95% CI: 15--24%) were similar, improvements were noted in patients undergoing combination PSC followed by RC-LND (31%; 95% CI: 25--38%) and RC-LND followed by adjuvant chemotherapy (26%; 95% CI: 21--34%). Although PSC increased pN0 rate 11.2 fold, the importance of salvage RC-LND was evidenced by the dramatic increase in OS in patients undergoing combination therapy (31% 5-year OS) vs. chemotherapy alone (14% 5-year OS). As acknowledged by the authors, frailty was not captured in the database, and may bias the results in favor of combination therapy.

INDEX PATIENT 4: METASTATIC DISEASE {#sec0040}
===================================

Local treatment (LT) in the metastatic setting has gained prominence for a wide range of solid tumors \[[@ref001]\]. Theoretically, this approach can limit disease progression by suppressing the source of tumor growth factors and new metastases as well as impact the patients' quality of life by eliminating the significant adverse effects brought on by local disease progression. For BCa, evidence is limited to only a few retrospective reviews. The most compelling data supporting the utility of intensive LT for metastatic BCa was compiled from the NCDB \[[@ref057]\]. Of 3,753 patients receiving systemic chemotherapy, 297 received high-intensity LT, defined as RC or≥50 Gy radiotherapy. The median OS was found to be significantly longer in patients receiving high-intensity LT than those receiving conservative LT (14.92 \[IQR, 9.82 to 30.72\] vs. 9.95 \[IQR, 5.29 to 17.08\] months, *p* \< 0.001). Furthermore, the subgroup receiving consolidative surgery (i.e. RC after chemotherapy) achieved even higher OS than the high-intensity LT group overall (17.71 \[IQR, 10.41 to not estimable\] vs. 12.42 \[IQR, 7.06 to 20.37\] months, *p* \< 0.001).

These findings were corroborated by subgroup analyses from earlier post chemotherapy cystectomy series \[[@ref058]\]. In small subgroups with clinical extraregional lymph node (*n* = 11) and visceral metastases (*n* = 9), 5-year survival was achieved by 15%. Not surprisingly, patients harboring visceral metastases fared worse than those with clinical lymph node metastases only after consolidative surgery.

RC may also be used towards palliating local symptoms brought on by disease progression, including bleeding, pain, dysuria and urinary obstruction. Of these, hematuria associated with bladder tumors causes significant morbidity and can be both difficult and expensive to treat. Invariably, some patients with intractable hematuria may require invasive procedures such as TURBT, urinary diversion, and ultimately RC. Having RC upfront may help avoid these unpleasant morbidities as well as the additional mortality risk associated with emergency surgery done in a desperation setting.

Metastesectomy {#sec0045}
--------------

The role of metastatectomy for mBCa is controversial despite several retrospective reports demonstrating feasibility \[[@ref059]\] ([Table 2](#blc-4-blc170130-t002){ref-type="table"}). As with any surgical procedure performed in the metastatic setting, patient selection is of paramount importance. In patients with heavy disease burden involving multiple organs, metastatectomy resulted in a dismal median OS of 7 months \[[@ref063]\]. Moreover, asymptomatic patients prior to metastatectomy suffered a decrease in performance status as a result of the surgery. Although no formal selection criteria exists for metastatectomy, adherence to the following general principles may enhance efficacy: patients who demonstrated response to chemotherapy, recurrence in the initial or sole metastatic site, resectable tumors with clear margins, and a period of disease stability without progression (3 months) \[[@ref064]\]. The small numbers in previous retrospective reviews on metastatectomy make it difficult to draw conclusions regarding the clinical characteristics predictive of treatment success \[[@ref061]\]. However, several studies have suggested favorable prognosis for patients with solitary pulmonary metastases \[[@ref059]\]. Ultimately, prospective trials are needed to test the efficacy of not only surgical extirpation of the primary disease, but also of metastatic lesions elsewhere.

###### 

Metastasectomy

  Study (year)             Number of patients  Metastatic site
  ----------------------- -------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Miller (1993)                    36          n/a
  Dodd (1999)                      50          Lymph nodes or abdominal/pelvic mass: *n* = 32; lung: *n* = 10; bone: *n* = 3, liver: *n* = 1
  Siefker-Radtke (2004)            31          Lymph nodes: *n* = 4; lung *n* = 24; brain: *n* = 2; subcutaneous metastasis: *n* = 1
  Lehmann (2009)                   44          Lymph nodes: *n* = 30; lung: *n* = 8; bone: *n* = 2; adrenal gland: *n* = 1; brain *n* = 1; small intestine: *n* = 1; subcutaneous metastasis: *n* = 1
  Kanzaki (2010)                   18          Lung: *n* = 18
  Matsuguma (2011)                 32          Lung: *n* = 32
  Abe (2014)                       42          Lymph node: *n* = 20; lung: *n* = 12; pelvic soft tissue: *n* = 3; local recurrence *n* = 2; subcutaneous metastases: *n* = 2; liver: *n* = 1; others *n* = 2

FEASIBILITY OF RADICAL CYSTECTOMY IN PATIENTS WITH METASTATIC BLADDER CANCER {#sec0050}
============================================================================

Advanced local disease may often be encountered in the cytoreductive setting, adding complexity to surgical extirpation. Several studies have focused on the feasibility of RC in locally advanced, T4 BCa \[[@ref066]\]. In a series of 20 consecutive pT4 BCa patients undergoing RC, Nagele et al. found few perioperative complications, including insignificant pulmonary embolism and acute renal failure in one patient and an enterocutaneous fistula in another \[[@ref067]\]. In another study, Moschini et al. found higher rate of transfusion and longer postoperative hospital stays for the cT4b patients, but perioperative complications as well as 30 day readmission rates were similar as those with cT1-3 UC \[[@ref066]\]. Al-Daghmin recently evaluated the feasibility of robotic-assisted radical cystectomy (RARC) for patients with pT4 UC. While complication rates were similar, the 30- and 90-day mortalities were higher for pT4 patients than those with≤pT3 disease \[[@ref068]\]. Furthermore, BMI has been found to be an independent predictor for postoperative complications \[[@ref069]\]. Negative margin rates for T4 disease ranged from 74.4 to 91.1% \[[@ref024]\].

IDENTIFYING APPROPRIATE CANDIDATES FOR CYTOREDUCTIVE SURGERY FOR RADICAL CYSTECTOMY, ROLE OF IMAGING. {#sec0055}
=====================================================================================================

As no formal criteria exist, general oncologic principles may help guide in selecting candidates with metastatic BCa for RC-LND. At this time, it is felt that patients who are most likely to benefit from PSC followed by RC-LND are those that: demonstrated response to chemotherapy, have a minimal metastatic burden, have resectable tumors, and/or a period (3 months) in which disease stability has been demonstrated without progression \[[@ref064]\]. In particular, retrospective studies have suggested prolonged survival in patients with oligometastatic LN or lung metastases after local control and even metastatectomy \[[@ref059]\]. In addition, host factors such as age, sex, and comorbidity as well as performance status may play vital roles in patient selection. Future advances in the understanding of the molecular mechanisms behind BCa oncogenesis may help to distinguish indolent from aggressive variants of mBCa. For example, Kim et al. used next-generation sequencing to identify genomic subsets of high-grade BCa associated with favorable and unfavorable outcomes post RC \[[@ref070]\]. Ultimately, the efficacy of aggressive surgical extirpation in the metastatic setting will need to be verified in well-designed prospective trials.

CONCLUSION {#sec0060}
==========

Surgical extirpation of the primary tumor may be an important component in the management of metastatic BCa. Existing retrospective data demonstrate efficacy in carefully selected patients, especially after favorable response to systemic chemotherapy. Surgical extirpation has been demonstrated to be feasible even with locally advanced disease in the post-chemo setting. Though highly morbid, perioperative outcomes after RC-LND have improved with the advent of minimally invasive surgery and enhanced postsurgical pathways. The time is ripe for well-designed, prospective, trials to test the efficacy of cystectomy for metastatic BCa.
